Patents by Inventor Su I. Yum
Su I. Yum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6251083Abstract: Devices and methods for utilizing dry chemistry dye indicator systems for body fluid analysis, such as glucose level provided by incorporating a porous membrane in a disposable patch. The devices also provide for microtitration of fluid samples in fixed volumetric openings containing indicator reagent. The devices provided are low cost due to efficient manufacturing methods provided.Type: GrantFiled: September 7, 1999Date of Patent: June 26, 2001Assignee: Amira MedicalInventors: Su I. Yum, Jeffrey N. Roe, Joel S. Douglas
-
Patent number: 6001390Abstract: Composition of matter for application to a body surface or membrane to administer pergolide by permeation through the body surface or membrane, the composition comprising pergolide to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the pergolide or pergolide and enhancer composition and methods for the transdermal administration of the pergolide and pergolide/enhancer composition.Type: GrantFiled: December 18, 1996Date of Patent: December 14, 1999Assignee: Alza CorporationInventors: Su I Yum, Melinda K. Nelson, Patricia S. Campbell
-
Patent number: 5633008Abstract: A method of administering nicotine transdermally in which a nicotine patch, capable of administering nicotine for at least 16 hours at rates that are efficacious in smoking cessation therapy, is applied in the morning upon waking and removed prior to sleep. This method is effective even though nicotine is not essential during sleep and many smokers experience morning craving.Type: GrantFiled: August 12, 1993Date of Patent: May 27, 1997Inventors: James L. Osborne, Melinda K. Nelson, David J. Enscore, Su I. Yum, Robert M. Gale, Donna D. Causey
-
Patent number: 5540665Abstract: The present invention provides a gas generating engine for driving a beneficial agent dispensing device. The engine comprising (a) a solid composition comprising an acidic compound or a basic compound, or a combination thereof, and (b) a means for maintaining substantially constant the surface area of the solid composition exposed to a reservoir fluid comprising water, or water and an acidic compound, or water and a basic compound, wherein in operation, the solid composition is exposed to the reservoir fluid which dissolves the solid composition and causes it to generate a gas, the gas being a driving fluid to dispense a beneficial agent. The present invention further provides a fluid driven dispensing device for delivering an agent into an environment of use, the device be driven by the gas generating engine.Type: GrantFiled: January 31, 1994Date of Patent: July 30, 1996Assignee: ALZA CorporationInventors: Stanley A. Mercado, Mark M. McPhee, Avtar S. Nat, Su I. Yum, Scott A. Bura
-
Patent number: 5508039Abstract: The present invention is directed to the transdermal administration of melatonin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device (10) comprising a matrix (12) adapted to be placed in melatonin- and permeation enhancer-transmitting relation with the skin site (18). The matrix (12) contains sufficient amounts of a permeation enhancer and of melatonin, in combination, to continuously administer to the skin (18) for a predetermined period of time the melatonin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of melatonin together with a skin permeation-enhancing amount of a suitable permeation enhancer. The invention further includes methods for time- and rate-patterned transdermal delivery of melatonin to simulate the natural circadian rhythmic profile of melatonin in mammals.Type: GrantFiled: June 13, 1994Date of Patent: April 16, 1996Assignee: ALZA CorporationInventors: F. Eugene Yates, Lina T. Taskovich, Su I. Yum, Nieves M. Crisologo
-
Patent number: 5500222Abstract: The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer.Type: GrantFiled: February 15, 1995Date of Patent: March 19, 1996Assignee: Alza CorporationInventors: Eun S. Lee, Diane E. Nedberge, Su I. Yum
-
Patent number: 5489281Abstract: A process for delivering a biocide to a container comprising admitting a biocide delivery device through an exit port of a urine container where the device is sized for passage through the exit port is disclosed.Type: GrantFiled: January 8, 1992Date of Patent: February 6, 1996Assignee: Alza CorporationInventors: Tyler Watanabe, Su I. Yum, Eun S. Lee, Ivan W. Chin
-
Patent number: 5462745Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration: and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.Type: GrantFiled: August 30, 1994Date of Patent: October 31, 1995Assignee: Alza CorporationInventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
-
Patent number: 5417675Abstract: The invention disclosed and claimed an apparatus that relates to a delivery system comprising a biocide, with the delivery system designed and shaped for passages through the exit port of a urine container into the container. The invention disclosed and claim pertains also to a method of preventing infection in a patient by using the apparatus connected to a patient through a catheter.Type: GrantFiled: January 8, 1992Date of Patent: May 23, 1995Assignee: Alza CorporationInventors: Tyler Watanabe, Su I. Yum, Fun S. Lee, Ivan W. Chin
-
Patent number: 5417676Abstract: An apparatus is disclosed comprising in combination (1) a container for receiving a fluid, and having an exit port, and (2) a delivery system designed for passage through the exit port into the container for releasing a biocide inside the container.Type: GrantFiled: January 8, 1992Date of Patent: May 23, 1995Assignee: Alza CorporationInventors: Tyler Watanabe, Su I. Yum, Eun S. Lee, Ivan W. Chin
-
Patent number: 5411740Abstract: The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer.Type: GrantFiled: February 8, 1994Date of Patent: May 2, 1995Assignee: ALZA CorporationInventors: Eun S. Lee, Diane E. Nedberge, Su I. Yum
-
Patent number: 5364630Abstract: Rate controlled transdermal nicotine delivery systems are disclosed which utilize an in-line adhesive to maintain the systems on the skin. The initial equilibrated concentration of nicotine in the nicotine reservoir and the adhesive is below saturation, preferably at a thermodynamic activity no greater than 0.50, and the reservoir comprises the nicotine dissolved in a material with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of nicotine in the reservoir is sufficient to prevent the activity of the nicotine in the reservoir from decreasing by more than about 75% and preferably no more than about 25% during the predetermined period of administration; and the thickness of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and, preferably at least 75% of the initial equilibrated nicotine loading is in the reservoir layer.Type: GrantFiled: June 21, 1993Date of Patent: November 15, 1994Assignee: Alza CorporationInventors: James L. Osborne, Melinda Nelson, David J. Enscore, Su I. Yum, Robert M. Gale
-
Patent number: 5344656Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.Type: GrantFiled: June 16, 1993Date of Patent: September 6, 1994Assignee: ALZA CorporationInventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
-
Patent number: 5342623Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.Type: GrantFiled: June 18, 1993Date of Patent: August 30, 1994Assignee: Alza CorporationInventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
-
Patent number: 5250028Abstract: A drug formulation chamber for an intravenous administration set is provided. The intravenous administration set includes a container of an IV fluid, a drip chamber, a drug formulation chamber, and an adapter-needle assembly. The drug formulation chamber has a fluid inlet and a fluid outlet for maintaining a flow of IV fluid through the chamber. A portion of the chamber wall is comprised of a material which is permeable to the drug but which prevents convective loss of the IV fluid. A transdermal-type drug delivery device is adhered to the semipermeable/microporous wall portion. Drug is delivered by the delivery device through the wall portion using permeation enhancers and into the flowing IV fluid. The device delivers drug into the IV fluid at a rate that is independent of the flow rate of IV fluid through the formulation chamber. The rate of drug delivery from the device into the IV fluid is controlled by either the wall portion or a membrane layer in the drug delivery device.Type: GrantFiled: August 9, 1991Date of Patent: October 5, 1993Assignee: ALZA CorporationInventors: Felix Theeuwes, Su I. Yum
-
Patent number: 5234424Abstract: An improved osmotic engine is disclosed. The osmotic engine is adapted to be used with an osmotically driven syringe which can be used to deliver a beneficial agent, such as a drug, at a pre-determined rate over an extended period of time. The osmotic engine has an exterior wall defining a compartment which contains an osmotic solute. The wall comprises a thin permeable and/or microporous material which is permeable to an external fluid such as water but is impermeable to the solute. The wall also has a delivery orifice drilled therethrough. A rigid non-dissolving ring-shaped wall support is provided for maintaining the shape of the engine during use. The wall support also provides an open fluid flow path extending from the semipermeable wall portion toward the delivery orifice. The open fluid flow path minimizes the time required for the engine to begin pumping.Type: GrantFiled: June 25, 1991Date of Patent: August 10, 1993Assignee: Alza CorporationInventors: Su I. Yum, Felix A. Landrau, James Z. Huang
-
Patent number: 5176665Abstract: The invention pertains to a delivery system comprising a biocide, with the delivery system designed and shaped for passage through the exit port of a urine container into the container.Type: GrantFiled: January 18, 1991Date of Patent: January 5, 1993Assignee: Alza CorporationInventors: Tyler Watanabe, Su I. Yum, Eun S. Lee, Ivan W. Chin
-
Patent number: 5160320Abstract: An agent formulator (30, 60) for an intravenous administration set (14) is provided. The intravenous administration set (14) includes a container (12) of an IV fluid (13), a drip chamber (22), an agent formulator (30, 60) and an adapter-needle assembly (28). The agent formulator (30, 60) has a fluid inlet (23) and a fluid outlet (25) for maintaining a flow of IV fluid (13 ) therethrough. A portion (36) of the formulator wall (32) is comprised of a window material which allows the agent to diffuse therethrough but which prevents convective loss of the IV fluid (13). A flow distributor (38, 68) is provided within the chamber for distributing the flow of IV fluid (13) along the interior surface of the window (36). A transdermal-type drug delivery device (40) is adhered to the exterior surface of the window (36). Drug is delivered by the delivery device (40) through the window (36) and into the flowing IV fluid (13).Type: GrantFiled: August 12, 1991Date of Patent: November 3, 1992Assignee: Alza CorporationInventors: Su I. Yum, Felix Theeuwes
-
Patent number: 5151093Abstract: An osmotically driven syringe (20, 60) is disclosed which can be used to deliver a beneficial agent such as a drug, at varying pre-determined rates over multiple periods of time. The syringe (20, 60) is driven by an osmotic engine (10) having a shaped wall (12) containing an osmotic agent (17) and/or a gas generating means (19), such as an effervescent couple. The wall (12) is composed of a semipermeable and/or microporous material which is permeable to an external liquid (e.g., water) but which is substantially impermeable to the osmotic agent (17) and the gas generated by the gas generating means (19). The wall (12) has a passageway (13) therethrough to provide a flow path for the driving fluid generated by the engine (10). The osmotic agent(s) (17) and/or the gas generating means (19) are placed in the engine (10) in such a way as to drive engine (10) at different pumping rates (R.sub.1, R.sub.2) over sequential periods of time (t.sub.o to t.sub.1 and t.sub.1 to t.sub.2).Type: GrantFiled: October 29, 1990Date of Patent: September 29, 1992Assignee: Alza CorporationInventors: Felix Theeuwes, Su I. Yum
-
Patent number: 5104390Abstract: A patient-care apparatus comprising a container for receiving a biological fluid, and a delivery device on the outside of the container, which device comprises a biocide that is released to the container for preventing the multiplication of and/or eliminating the presence of unwanted pathogens in the container.Type: GrantFiled: April 2, 1990Date of Patent: April 14, 1992Assignee: ALZA CorporationInventors: Su I. Yum, Felix Theeuwes